睿知中国疾病研究地图
候选清单0

重庆重庆医科大学

重庆医科大学附属第一医院

First Affiliated Hospital of Chongqing Medical University

在本站收录的 53 种疾病中,这家医院列在其中 21 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

这家医院的官网还没有核对。

联系这家医院

重庆医科大学附属第一医院的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 鼻咽癌Nasopharyngeal carcinoma8 篇牵头论文
  2. 食管鳞状细胞癌Oesophageal squamous cell carcinoma7 篇牵头论文
  3. 肝细胞癌Hepatocellular carcinoma64 篇牵头论文牵头 1 项开放试验
  4. 胃癌Stomach cancer35 篇牵头论文
  5. 骨肉瘤Osteosarcoma25 篇牵头论文
  6. 胃肠道间质瘤Gastrointestinal stromal tumour12 篇牵头论文牵头 1 项开放试验
  7. 神经母细胞瘤Neuroblastoma1 篇牵头论文
  8. 尤文肉瘤Ewing sarcoma2 篇牵头论文
  9. 多发性骨髓瘤Multiple myeloma4 篇牵头论文
  10. 再生障碍性贫血Aplastic anaemia1 篇牵头论文
  11. β 地中海贫血Beta thalassaemia1 篇牵头论文
  12. 视神经脊髓炎谱系疾病Neuromyelitis optica spectrum disorder8 篇牵头论文
  13. IgG4相关性疾病IgG4-related disease2 篇牵头论文
  14. 重症肌无力Myasthenia gravis10 篇牵头论文
  15. 抗 NMDA 受体脑炎Anti-NMDA receptor encephalitis1 篇牵头论文
  16. 特发性肺纤维化Idiopathic pulmonary fibrosis3 篇牵头论文
  17. 肌萎缩侧索硬化症Amyotrophic lateral sclerosis5 篇牵头论文
  18. 杜氏肌营养不良Duchenne muscular dystrophy1 篇牵头论文
  19. 白塞病Behçet disease28 篇牵头论文
  20. IgA 肾病IgA nephropathy1 篇牵头论文
  21. 遗传性大疱性表皮松解症Inherited epidermolysis bullosa1 篇牵头论文

未列出的收录疾病:肝母细胞瘤、视网膜母细胞瘤、脊索瘤、B 细胞急性淋巴细胞白血病、噬血细胞性淋巴组织细胞增生症、血友病 A、非典型溶血性尿毒症综合征、血栓性血小板减少性紫癜、范可尼贫血、烟雾病、肝豆状核变性、胆道闭锁、大动脉炎、肝包虫病、肺淋巴管平滑肌瘤病、脊髓性肌萎缩症、法布雷病、庞贝病、Alport 综合征、戈谢病、尼曼-匹克病 C 型、成骨不全症、原发性胆汁性胆管炎、原发性硬化性胆管炎、先天性膈疝、先天性巨结肠、遗传性血管性水肿、家族性腺瘤性息肉病、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

鼻咽癌

Nasopharyngeal carcinoma

2021–2025 年中国大陆作者发表的 2,375 篇鼻咽癌 PubMed 英文论文中,这家医院牵头了 8 篇,占 0.3%。

牵头论文
8
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 1120222023: 1120232024: 1120242025: 332025

重庆有 6 家医院列在鼻咽癌下全国有 176 家医院列在鼻咽癌下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的鼻咽癌开放试验。

这些数字背后的记录
研究主题诱导/同步化疗放疗技术复发与转移
论文中的科室肿瘤内科耳鼻喉/头颈外科影像/核医学科
牵头的论文8
  1. Maintenance treatment with oral anticancer agents after first-line chemotherapy in patients with recurrent or metastatic nasopharyngeal carcinoma: a systematic review and meta-analysis.2025European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  2. TGF-β-induced acetylation of KLF5 drives TNFAIP2 transcription and EMT in nasopharyngeal carcinoma: Unveiling a novel regulatory mechanism.2025Experimental cell research
  3. Sesamin Exerts Anti-Tumor Activity in Nasopharyngeal Carcinoma Through Inducing Autophagy and Reactive Oxygen Species Production.2025Frontiers in bioscience (Landmark edition)
  4. Novel prediction model combining PET/CT metabolic parameters, inflammation markers, and TNM stage: prospects for personalizing prognosis in nasopharyngeal carcinoma.2024Annals of nuclear medicine
  5. Methylated tumor suppressor gene SCARA5 inhibits the proliferation, migration and invasion of nasopharyngeal carcinoma.2023Epigenomics
  6. The safety and efficacy of gemcitabine and cisplatin (GP)-based induction chemotherapy plus concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a meta-analysis.2022European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  7. The evaluation of adding induction chemotherapy to concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma: a meta-analysis.2021European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  8. The prognostic role of prognostic nutritional index in nasopharyngeal carcinoma: A systematic review and meta-analysis.2021International journal of clinical oncology
PubMed 以外找到的论文(未计入)7
  1. Current Status of Induction Chemotherapy in Locally Advanced Nasopharyngeal Carcinoma2025Journal of Innovations in Medical Research论文
  2. Triple-modality nanotheranostics for nasopharyngeal carcinoma: porphyrin-driven photothermal-chemo-radiosensitization with MRI-guided precision2025Frontiers in Nanotechnology论文
  3. A Review of the Role of DWI in Radiation Therapy Planning and Treatment Response Assessment for NPC Management2023Current Research in Medical Sciences论文
  4. Clinical Researches of Magnetic Resonance Diffusion Weighted Imaging in Radiotherapy of Nasopharyngeal Carcinoma2023Journal of Clinical Medicine Research论文
  5. Additional file 1 of A two-stage genome-wide association study to identify novel genetic loci associated with acute radiotherapy toxicity in nasopharyngeal carcinoma2022Figshare数据集
  6. Toripalimab plus bevacizumab as first-line treatment for advanced hepatocellular carcinoma: A single-arm phase II study.2022Journal of Clinical Oncology会议摘要
  7. The microRNA-451a/chromosome segregation 1-like axis suppresses cell proliferation, migration, and invasion and induces apoptosis in nasopharyngeal carcinoma2021Figshare数据集

打开 PubMed 检索ClinicalTrials.gov

癌症

食管鳞状细胞癌

Oesophageal squamous cell carcinoma

2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 7 篇,占 0.2%。

牵头论文
7
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 2220222023: 1120232024: 2220242025: 002025

重庆有 7 家医院列在食管鳞状细胞癌下全国有 191 家医院列在食管鳞状细胞癌下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的食管鳞状细胞癌开放试验。

这些数字背后的记录
研究主题新辅助与综合治疗免疫治疗分子标志物与基因
论文中的科室消化/肝病科

这些论文过半是实验室或动物研究。

牵头的论文7
  1. Senolytic elimination of therapy-induced senescent cells by ABT-263 improves chemotherapeutic efficacy in esophageal squamous cell carcinoma.2026Biochemical pharmacology
  2. Romidepsin exhibits anti-esophageal squamous cell carcinoma activity through the DDIT4-mTORC1 pathway.2024Cancer gene therapy
  3. SH2D4A inhibits esophageal squamous cell carcinoma progression through FAK/PI3K/AKT signaling pathway.2024Cellular signalling
  4. Neoadjuvant camrelizumab plus chemotherapy in locally advanced oesophageal squamous cell carcinoma: a retrospective cohort study.2023BMC surgery免费全文
  5. Long noncoding RNA GK-IT1 promotes esophageal squamous cell carcinoma by regulating MAPK1 phosphorylation.2022Cancer medicine免费全文
  6. Untargeted metabolomics analysis of esophageal squamous cell cancer progression.2022Journal of translational medicine免费全文
  7. Survival differences between chemotherapy and chemoradiotherapy in metastatic esophageal cancer: a propensity score-matched study based on the SEER database.2021Annals of palliative medicine
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. A Study of CS1001 in Subjects With Esophageal Squamous Cell Carcinoma已完成NCT04187352研究中心III期2019-12 启动
PubMed 以外找到的论文(未计入)12
  1. Combining the Albumin-to-fibrinogen ratio and pathologic factors predicts survival in surgically treated patients with esophageal squamous cell carcinoma2024ONCOLOGIE论文
  2. PREDICTIVE VALUE OF RCCEP IN THE OUTCOME OF PATIENTS WITH ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA TREATED WITH CAMRELIZUMAB2024Journal of Pharmaceutical and Medical Research论文
  3. Additional file 2 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figshare数据集
  4. Additional file 3 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figshare数据集
  5. Additional file 4 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figshare数据集
  6. Additional file 5 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figshare数据集
  7. Additional file 1 of PABPC1-induced stabilization of IFI27 mRNA promotes angiogenesis and malignant progression in esophageal squamous cell carcinoma through exosomal miRNA-21-5p2022Figshare数据集
  8. Additional file 6 of Silencing of histone deacetylase 3 suppresses the development of esophageal squamous cell carcinoma through regulation of miR-494-mediated TGIF12022Figshare数据集
  9. Additional file 7 of Heparanase is a prognostic biomarker independent of tumor purity and hypoxia based on bioinformatics and immunohistochemistry analysis of esophageal squamous cell carcinoma2022Figshare数据集
  10. Capsaicin inhibits migration and invasion via inhibiting epithelial-mesenchymal transition in esophageal squamous cell carcinoma by up-regulation of claudin-3 expression2022Journal of Functional Foods论文
  11. Knock-down of long non-coding RNA GK-IT1 inhibits proliferation and promotes apoptosis in esophageal carcinoma cells2021DOAJ (DOAJ: Directory of Open Access Journals)论文
  12. LncRNA HCP5 promotes malignant cell behaviors in esophageal squamous cell carcinoma via the PI3K/AKT/mTOR signaling2021Figshare数据集

打开 PubMed 检索ClinicalTrials.gov

癌症

肝细胞癌

Hepatocellular carcinoma

2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 64 篇,占 0.4%。

牵头论文
64
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 9920212022: 8820222023: 131320232024: 191920242025: 13132025

重庆有 5 家医院列在肝细胞癌下全国有 192 家医院列在肝细胞癌下

这家医院参与的开放试验 3

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 即将招募
    Ivarmacitinib Combined With Camrelizumab and Apatinib for Unresectable Advanced Hepatocellular Carcinoma With Acquired Resistance to Immune Checkpoint Therapy: A Single-Arm Exploratory Clinical Study
    分期
    II期
    开始
    2026-01
    登记号
    NCT07324473

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:重庆医科大学附属第一医院重庆

  2. 正在招募
    ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
    分期
    II期
    开始
    2025-06
    登记号
    NCT07327034

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 39 家列出的医院为研究中心上海、北京、南京、南宁、南昌、南通、合肥、天津、广州、徐州、成都、杭州、桂林、武汉、沈阳、济南、福州、西安、赣州、郑州、重庆、银川、长春、长沙

  3. 即将招募
    Surgery vs. Watch-and-Wait Strategy in Complete Responders for Hepatocellular Carcinoma
    分期
    不分期
    开始
    2026-12
    登记号
    NCT07866612

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:四川大学华西医院;另有 8 家列出的医院为研究中心上海、北京、南京、广州、成都、福州、重庆

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题复发与预后免疫与靶向药物影像、人工智能与早期发现
论文中的科室普外/肝胆胰外科消化/肝病科病理/检验科影像/核医学科
牵头的论文64
  1. Comparison of Postoperative Adjuvant CTACE vs DEB-TACE Combined with Tislelizumab and Lenvatinib in BCLC Stage B/C Hepatocellular Carcinoma: A Propensity Score-Matched Analysis of Survival Outcomes.2026Academic radiology
  2. Self-confined catalytic DNA circuit for on-site nonenzymatic amplified microRNA imaging.2026Biosensors & bioelectronics
  3. MTFR2-Mediated Fission Drives Fatty Acid and Mitochondrial Co-Transfer from Hepatic Stellate Cells to Tumor Cells Fueling Oncogenesis.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  4. Discovery of novel diagnostic biomarkers of hepatocellular carcinoma associated with immune infiltration.2025Annals of medicine免费全文
  5. Current status and perspectives of molecular mechanisms of gender difference in hepatocellular carcinoma: The tip of the iceberg?2025Bioscience trends
  6. Advancements in second-line treatment research for hepatocellular carcinoma.2025Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  7. Relationships Among Serological Indicators and In Vitro High-Throughput Drug Sensitivity Screening Results in Patients with Hepatocellular Carcinoma.2025Combinatorial chemistry & high throughput screening
  8. Efficacy of Tislelizumab plus Lenvatinib in hepatocellular carcinoma after curative hepatectomy: a real-world study.2025Frontiers in immunology免费全文
  9. Liver resection versus radiofrequency ablation for solitary small hepatocellular carcinoma measuring ≤3 cm: a systematic review and meta-analysis.2025International journal of surgery (London, England)免费全文
  10. Impact of HIV Infection on Hepatocellular Carcinoma: A Long-Term Prognostic Analysis.2025Journal of laparoendoscopic & advanced surgical techniques. Part A
  11. M2 macrophages and tumor cells engage in a metabolic feedback loop to drive HCC progression.2025Scientific reports免费全文
  12. Prognostic impact of tertiary lymphoid structures and cancer-associated fibroblasts in hepatocellular carcinoma with portal vein tumor thrombus.2025Scientific reports免费全文
  13. Comparison of the efficacy of laparoscopic hepatectomy and radiofrequency ablation for small hepatocellular carcinoma: A retrospective study.2025World journal of gastroenterology免费全文
  14. Unraveling the therapeutic potential of Calculus Bovis in liver cancer: A novel step for targeted cancer treatment.2025World journal of gastroenterology免费全文
  15. Laparoscopic liver resection utilizing the ventral avascular area of the inferior vena cava: A retrospective cohort study.2025World journal of gastroenterology免费全文
  16. Surgical resection of late-stage hepatocellular carcinoma for patients having undergone combined HAIC, targeted and immunotherapy.2024Asian journal of surgery
  17. The immune response of hepatocellular carcinoma after locoregional and systemic therapies: The available combination option for immunotherapy.2024Bioscience trends
  18. Hepatic arterial infusion chemotherapy (HAIC) combined with Tislelizumab and Lenvatinib for unresectable hepatocellular carcinoma: a retrospective single-arm study.2024Cellular oncology (Dordrecht, Netherlands)免费全文
  19. Inhibition of SIRT7 promotes STAT1 activation and STAT1-dependent signaling in hepatocellular carcinoma.2024Cellular signalling
  20. Development and Validation of a Risk Prediction Algorithm for Evaluating the Efficacy of Postoperative Adjuvant TACE Therapy for Hepatocellular Carcinoma.2024Combinatorial chemistry & high throughput screening
  21. Tumor suppressor CLCA1 inhibits angiogenesis via TGFB1/SMAD/VEGF cascade and sensitizes hepatocellular carcinoma cells to Sorafenib.2024Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  22. CLCA1, a tumour suppressor in hepatocellular carcinoma.2024Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  23. Preoperative CT features for characterization of vessels that encapsulate tumor clusters in hepatocellular carcinoma.2024European journal of radiology
  24. Tumor-associated macrophages and CD8+ T cells: dual players in the pathogenesis of HBV-related HCC.2024Frontiers in immunology免费全文
  25. Prognostic value of tertiary lymphoid structures in hepatocellular carcinoma: a meta-analysis and systematic review.2024Frontiers in immunology免费全文
  26. FBXO family genes promotes hepatocellular carcinoma via ubiquitination of p53.2024Journal of cancer research and clinical oncology免费全文
  27. Risk of HBV reactivation in HCC patients undergoing combination therapy of PD-1 inhibitors and angiogenesis inhibitors in the antiviral era.2024Journal of cancer research and clinical oncology免费全文
  28. PLAG1 interacts with GPX4 to conquer vulnerability to sorafenib induced ferroptosis through a PVT1/miR-195-5p axis-dependent manner in hepatocellular carcinoma.2024Journal of experimental & clinical cancer research : CR免费全文
  29. Effect of Preoperative Malnutrition Based on Albumin and BMI on Hepatocellular Carcinoma Surgery and Prediction of Risk Factors of Complications.2024Journal of gastrointestinal cancer
  30. Construction of in-situ self-assembled agent for NIR/PET dual-modal imaging and photodynamic therapy for hepatocellular cancer.2024Journal of nanobiotechnology免费全文
  31. MTFR2-dependent mitochondrial fission promotes HCC progression.2024Journal of translational medicine免费全文
  32. Combination strategies in advanced hepatocellular carcinoma: the CARES-310 trial.2024Lancet (London, England)
  33. Adjuvant therapy in hepatocellular carcinoma: the IMbrave050 trial.2024Lancet (London, England)
  34. Deciphering the oncogenic potential of ADAM9 in hepatocellular carcinoma through bioinformatics and experimental approaches.2024Scientific reports免费全文
  35. An ER-Horse Detonating Stress Cascade for Hepatocellular Carcinoma Nanotherapy.2023ACS nano
  36. miR-29a-5p regulates the malignant biological process of liver cancer cells through ARID2 regulation of EMT.2023Advances in clinical and experimental medicine : official organ Wroclaw Medical University
  37. Establishment of a prognostic signature based on fatty acid metabolism genes in HCC associated with hepatitis B.2023BMC gastroenterology免费全文
  38. The expression of interleukin-1β in patients with chronic hepatitis B treated with pegylated-interferon-alpha combined with tenofovir disoproxil fumarate and monotherapy.2023BMC gastroenterology免费全文
  39. Correlation of endoplasmic reticulum stress patterns with the immune microenvironment in hepatocellular carcinoma: a prognostic signature analysis.2023Frontiers in immunology免费全文
  40. Based on disulfidptosis-related glycolytic genes to construct a signature for predicting prognosis and immune infiltration analysis of hepatocellular carcinoma.2023Frontiers in immunology免费全文
  41. T-cell exhaustion signatures characterize the immune landscape and predict HCC prognosis via integrating single-cell RNA-seq and bulk RNA-sequencing.2023Frontiers in immunology免费全文
  42. LncRNA RPPH1 acts as a molecular sponge for miR-122 to regulate Wnt1/β-catenin signaling in hepatocellular carcinoma.2023International journal of medical sciences免费全文
  43. Comparison of different adjuvant therapy regimen efficacies in patients with high risk of recurrence after radical resection of hepatocellular carcinoma.2023Journal of cancer research and clinical oncology免费全文
  44. Integrated proteogenomic characterization reveals an imbalanced hepatocellular carcinoma microenvironment after incomplete radiofrequency ablation.2023Journal of experimental & clinical cancer research : CR免费全文
  45. Frontline resection or liver transplantation in patients with single-nodule hepatocellular carcinoma.2023Liver international : official journal of the International Association for the Study of the Liver
  46. Elucidating Cuproptosis-Associated Genes in the Progression from Nash to HCC Using Bulk and Single-Cell RNA Sequencing Analyses and Experimental Validation.2023Medicina (Kaunas, Lithuania)免费全文
  47. An integrated analysis of Dynamin 1 Like: A new potential prognostic indicator in hepatocellular carcinoma.2023Molecular carcinogenesis
  48. Eupalinolide B inhibits hepatic carcinoma by inducing ferroptosis and ROS-ER-JNK pathway.2022Acta biochimica et biophysica Sinica免费全文
  49. A well-matched marriage of immunotherapy and radiofrequency ablation to reduce the relapse and progression of hepatocellular carcinoma.2022Bioscience trends
  50. Hepatic stellate cell exosome-derived circWDR25 promotes the progression of hepatocellular carcinoma via the miRNA-4474-3P-ALOX-15 and EMT axes.2022Bioscience trends
  51. Correlation between Immunohistochemical Markers in Hepatocellular Carcinoma Cells and In Vitro High-Throughput Drug Sensitivity Screening.2022Canadian journal of gastroenterology & hepatology免费全文
  52. SLC17A2 Expression Correlates with Prognosis and Immune Infiltrates in Hepatocellular Carcinoma.2022Combinatorial chemistry & high throughput screening
  53. Genomic analysis quantifies pyroptosis in the immune microenvironment of HBV-related hepatocellular carcinoma.2022Frontiers in immunology免费全文
  54. Clinical features and outcomes of NAFLD-related hepatocellular carcinoma.2022The Lancet. Oncology
  55. Four-year experience with more than 1000 cases of total laparoscopic liver resection in a single center.2022World journal of gastroenterology免费全文
  56. Circular RNA circSP3 promotes hepatocellular carcinoma growth by sponging microRNA-198 and upregulating cyclin-dependent kinase 4.2021Aging免费全文
  57. Successful conversion therapy through gastric transcatheter chemoembolization in advanced gastric cancer: A case report.2021Asian journal of surgery
  58. Comprehensive analyses of competing endogenous RNA networks reveal potential biomarkers for predicting hepatocellular carcinoma recurrence.2021BMC cancer免费全文
  59. An angiogenesis-related long noncoding RNA signature correlates with prognosis in patients with hepatocellular carcinoma.2021Bioscience reports免费全文
  60. The diagnostic potential of gut microbiome for early hepatitis B virus-related hepatocellular carcinoma.2021European journal of gastroenterology & hepatology
  61. Integrating transcriptomes and somatic mutations to identify RNA methylation regulators as a prognostic marker in hepatocellular carcinoma.2021Hepatobiliary & pancreatic diseases international : HBPD INT
  62. Identification of hub genes and candidate drugs in hepatocellular carcinoma by integrated bioinformatics analysis.2021Medicine免费全文
  63. IGF2BP1 Promotes the Liver Cancer Stem Cell Phenotype by Regulating MGAT5 mRNA Stability by m6A RNA Methylation.2021Stem cells and development
  64. Sintilimab plus IBI305 for hepatocellular carcinoma.2021The Lancet. Oncology
中文论文(未计入)2
  1. [Correlation of peritumoral circWDR25 expression with the prognosis of patients with hepatocellular carcinoma after curative resection].2021Nan fang yi ke da xue xue bao = Journal of Southern Medical University免费全文
  2. [Down-regulating the expression of hypoxia-induced fatty acid binding protein 5 (FABP5) inhibits tumor angiogenesis in Huh7 cells].2021Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology
它在 ClinicalTrials.gov 上的全部试验(任何状态)8
  1. Ivarmacitinib Combined With Camrelizumab and Apatinib for Unresectable Advanced Hepatocellular Carcinoma With Acquired Resistance to Immune Checkpoint Therapy: A Single-Arm Exploratory Clinical Study即将招募NCT07324473牵头方II期2026-01 启动
  2. Surgery vs. Watch-and-Wait Strategy in Complete Responders for Hepatocellular Carcinoma即将招募NCT07866612研究中心不分期2026-12 启动
  3. ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression正在招募NCT07327034研究中心II期2025-06 启动
  4. A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma进行中,不再招募NCT04712643研究中心III期2021-03 启动
  5. A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation进行中,不再招募NCT04639180研究中心III期2021-04 启动
  6. Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC已完成NCT04723004研究中心III期2020-10 启动
  7. Dual TORC1/TORC2 Inhibitor ATG-008 (CC-223) in HBV Positive Advanced Hepatocellular Carcinoma (HCC) Subjects已终止NCT03591965研究中心II期2018-08 启动
  8. A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)已完成NCT03412773研究中心III期2017-12 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胃癌

Stomach cancer

2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 35 篇,占 0.4%。

牵头论文
35
2021–2025 年
牵头试验
5
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
3
由其他机构牵头
每年牵头的论文数
2021: 8820212022: 3320222023: 8820232024: 111120242025: 552025

重庆有 6 家医院列在胃癌下全国有 218 家医院列在胃癌下

这家医院参与的开放试验 3

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
    分期
    III期
    开始
    2026-04
    登记号
    NCT07385703

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 62 家列出的医院为研究中心上海、临沂、乌鲁木齐、兰州、北京、南京、南充、南昌、厦门、合肥、天津、太原、安阳、常州、广州、徐州、成都、扬州、承德、昆明、杭州、武汉、汕头、沈阳、洛阳、济南、海口、石家庄、福州、苏州、西安、郑州、重庆、长春、长沙、青岛

  2. 正在招募
    A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
    分期
    III期
    开始
    2024-11
    登记号
    NCT06532006

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 34 家列出的医院为研究中心上海、乌鲁木齐、兰州、北京、南京、南昌、厦门、合肥、哈尔滨、天津、太原、常州、广州、徐州、成都、杭州、石家庄、福州、蚌埠、郑州、重庆、银川、长春、长沙、青岛

  3. 正在招募
    A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
    分期
    I/II期
    开始
    2022-01
    登记号
    NCT05150691

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 34 家列出的医院为研究中心上海、北京、南宁、厦门、合肥、天津、安阳、广州、徐州、无锡、杭州、武汉、沈阳、济南、温州、烟台、石家庄、蚌埠、西安、郑州、重庆、长春、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题手术影像与人工智能早期发现与内镜
论文中的科室消化/肝病科影像/核医学科病理/检验科肿瘤内科
牵头的论文35
  1. Burden, trends, driving factors, and predictions of gastric cancer: a cross-national comparative analysis of China, Japan, and South Korea.2025BMC cancer免费全文
  2. Laparoscopic gastrectomy versus open gastrectomy for gastric cancer in patients among octogenarians: a meta-analysis.2025Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  3. Safety and efficacy of laparoscopic radical gastrectomy after neoadjuvant chemotherapy plus immunotherapy: a retrospective cohort study.2025Frontiers in immunology免费全文
  4. Prognostic risk model of gastric adenocarcinoma based on exosome-related genes.2025Medicine免费全文
  5. Logical Analysis of Multiple miRNAs with Isothermal Molecular Classifiers Based on LATE-RCA.2025Nano letters
  6. Effects of HMGA2 on the biological characteristics and stemness acquisition of gastric cancer cells.2024Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology
  7. The effect of tumor budding on patients with gastric cancer.2024Asian journal of surgery
  8. A Retrospective Observational Study of Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer and Colorectal Cancer From a Single Center in the Recent 5 years.2024Cancer control : journal of the Moffitt Cancer Center免费全文
  9. Precutting Endoscopic Band Ligation-Assisted Resection Is Safe and Effective for Treating Gastric Submucosal Tumors from the Muscularis Propria.2024Digestive diseases and sciences
  10. YTHDF1 Promotes Proliferation and Inhibits Apoptosis of Gastric Cancer Cells via Upregulating TCF7 mRNA Translation.2024Frontiers in bioscience (Landmark edition)
  11. Safety and Feasibility of Electro-Vaporization of Ligamentum Teres Hepatis in Totally Laparoscopic Gastrectomy.2024Journal of laparoendoscopic & advanced surgical techniques. Part A
  12. FTO promotes gastric cancer progression by modulating MAP4K4 expression via demethylation in an m6A-dependent manner.2024Medical oncology (Northwood, London, England)
  13. Preoperative CT-based radiomics and deep learning model for predicting risk stratification of gastric gastrointestinal stromal tumors.2024Medical physics
  14. Predictive Value of Preoperative Peripheral Blood Inflammatory Markers for Surgical Site Infection in Laparoscopic Radical Gastrectomy for Gastric Cancer.2024Surgical infections
  15. Disparities, Trends, and Predictions to 2040 in Gastrointestinal Cancer Incidence, Mortality in the United States.2024The American journal of gastroenterology免费全文
  16. Precutting endoscopic band ligation-assisted resection versus endoscopic submucosal dissection in patients with small gastric submucosal tumors originating from the muscularis propria: study protocol of a randomized controlled trial.2024Trials免费全文
  17. Does previous gastrectomy history affect the surgical outcomes of laparoscopic cholecystectomy?2023BMC surgery免费全文
  18. Effectiveness and safety of self-pulling and latter transected reconstruction in totally laparoscopic total gastrectomy: a comparison with laparoscopic-assisted total gastrectomy.2023BMC surgery免费全文
  19. DNA methylation-related lncRNAs predict prognosis and immunotherapy response in gastric cancer.2023Journal of cancer research and clinical oncology免费全文
  20. The Effect of Surgical Approach on Clinical Outcomes in 535 Patients with Remnant Gastric Cancer.2023Journal of laparoendoscopic & advanced surgical techniques. Part A
  21. Short-Term and Long-Term Outcomes of Liver Cirrhosis in Gastric Neoplasm Patients Undergoing Endoscopic Submucosal Dissection.2023Journal of laparoendoscopic & advanced surgical techniques. Part A
  22. Red blood cell distribution width has a prognostic value for gastric cancer patients after gastrectomy: A pooling-up analysis.2023Medicine免费全文
  23. Comparison of endoscopic submucosal dissection versus surgery for early gastric cancer in the elderly: a pooled analysis.2023World journal of surgical oncology免费全文
  24. The advanced lung cancer inflammation index is a prognostic factor for gastrointestinal cancer patients undergoing surgery: a systematic review and meta-analysis.2023World journal of surgical oncology免费全文
  25. A nomogram to predict the survival of gastric cancer patients who underwent radical gastrectomy in west China.2022Asian journal of surgery
  26. Does Chronic Kidney Disease Affect the Surgical Outcome and Prognosis of Patients with Gastric Cancer? A Meta-Analysis.2022Nutrition and cancer
  27. Identification and Characterization of the Roles of circCASP9 in Gastric Cancer Based on a circRNA-miRNA-mRNA Regulatory Network.2022Oxidative medicine and cellular longevity免费全文
  28. LncRNA SNHG3 promotes gastric cancer cell proliferation and metastasis by regulating the miR-139-5p/MYB axis.2021Aging免费全文
  29. The influence of metabolic syndrome on gastric cancer: A meta-analysis.2021Asian journal of surgery
  30. Successful conversion therapy through gastric transcatheter chemoembolization in advanced gastric cancer: A case report.2021Asian journal of surgery
  31. A simple predictive index for larger estimated blood loss during laparoscopy-assisted total gastrectomy.2021Asian journal of surgery
  32. The outcome of young vs. old gastric cancer patients following gastrectomy: a propensity score matching analysis.2021BMC surgery免费全文
  33. Novel endoscopic management for small gastric submucosal tumors: A single-center experience (with video).2021Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  34. Upregulation of ZHX2 predicts poor prognosis and is correlated with immune infiltration in gastric cancer.2021FEBS open bio免费全文
  35. Effect of endoscopic resection on short-term surgical outcomes of subsequent laparoscopic gastrectomy: a meta-analysis.2021World journal of surgical oncology免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)10
  1. Predictive Effect of Abdominal Fat and Muscle Area Calculated Based on Abdominal CT on Gastric Cancer Patients状态不明NCT06606912牵头方2012-01 启动
  2. SBRT-LDRT-Cadonilimab for Advanced Gastric, Colorectal and Ovarian Cancers With Peritoneal Metastases进行中,不再招募NCT06940921牵头方(推断)I/II期2025-03 启动
  3. The Effect of Environmental Factors on Gastric Cancer Based on Macrogenome进行中,不再招募NCT06854146牵头方(推断)2024-11 启动
  4. Predictive Value of Air Pollution and Metabolomics for Gastric Cancer.进行中,不再招募NCT06641700牵头方(推断)2024-10 启动
  5. The Association Between Microplastics and Macrogenomics and Metabolomics in Gastric Cancer进行中,不再招募NCT06856382牵头方(推断)2024-12 启动
  6. Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.正在招募NCT07385703研究中心III期2026-04 启动
  7. A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer正在招募NCT06532006研究中心III期2024-11 启动
  8. A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors正在招募NCT05150691研究中心I/II期2022-01 启动
  9. Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.已终止NCT05111626研究中心III期2022-03 启动
  10. PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer进行中,不再招募NCT05180734研究中心III期2022-02 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

骨肉瘤

Osteosarcoma

2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 25 篇,占 1.1%。

牵头论文
25
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 4420212022: 7720222023: 4420232024: 6620242025: 332025

重庆有 23 家医院列在骨肉瘤下全国有 742 家医院列在骨肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。

这些数字背后的记录
论文中的科室肿瘤内科

这些论文过半是实验室或动物研究。

牵头的论文25
  1. Co-encapsulation of bromelain and doxorubicin in acid-responsive nanogels for enhanced chemotherapy via tumor ECM degradation.2026Journal of biomaterials science. Polymer edition
  2. Integrative single-cell and bulk RNA-seq analysis identifies lactylation-related signature in osteosarcoma.2025Functional & integrative genomics
  3. Hino-Fe Chelate Suppresses Osteosarcoma Progression through Dual Induction of Ferroptosis and NLRC4-mediated Pyroptosis: Mechanisms and Therapeutic Implications.2025International journal of biological sciences
  4. Large Language Model-Assisted Genotoxic Metal-Phenolic Nanoplatform for Osteosarcoma Therapy.2025Small (Weinheim an der Bergstrasse, Germany)
  5. Targeting PERK-ATF4-P21 axis enhances the sensitivity of osteosarcoma HOS cells to Mppα-PDT.2024Aging
  6. Casticin induces ferroptosis in human osteosarcoma cells through Fe2+ overload and ROS production mediated by HMOX1 and LC3-NCOA4.2024Biochemical pharmacology
  7. Advances on immunotherapy for osteosarcoma.2024Molecular cancer
  8. Pyropheophorbide-α methyl ester-mediated photodynamic therapy triggers pyroptosis in osteosarcoma cells via the ROS/caspase-3/GSDME pathway.2024Photodiagnosis and photodynamic therapy
  9. Synergistic induction of ferroptosis by targeting HERC1-NCOA4 axis to enhance the photodynamic sensitivity of osteosarcoma.2024Redox biology
  10. RARRES2 is involved in the "lock-and-key" interactions between osteosarcoma stem cells and tumor-associated macrophages.2024Scientific reports
  11. High Expression of PKMYT1 Predicts Poor Prognosis and Aggravates the Progression of Osteosarcoma via the NF-κB Pathway in MG63 Cells.2023Current cancer drug targets
  12. Genipin Inhibits the Development of Osteosarcoma through PI3K/AKT Signaling Pathway.2023Current pharmaceutical design
  13. DEPDC1 and KIF4A synergistically inhibit the malignant biological behavior of osteosarcoma cells through Hippo signaling pathway.2023Journal of orthopaedic surgery and research
  14. Capsaicin Reduces Cancer Stemness and Inhibits Metastasis by Downregulating SOX2 and EZH2 in Osteosarcoma.2023The American journal of Chinese medicine
  15. A Novel Ferroptosis-Related Gene Signature for Prognosis Prediction in Ewing Sarcoma.2022Analytical cellular pathology (Amsterdam)
  16. Construction of a Prognosis-Related Gene Signature by Weighted Gene Coexpression Network Analysis in Ewing Sarcoma.2022Computational and mathematical methods in medicine
  17. Homologous targeting nanoparticles for enhanced PDT against osteosarcoma HOS cells and the related molecular mechanisms.2022Journal of nanobiotechnology
  18. Schisandrin B suppresses osteosarcoma lung metastasis in vivo by inhibiting the activation of the Wnt/β‑catenin and PI3K/Akt signaling pathways.2022Oncology reports
  19. Theaflavin-3,3'-Digallate Plays a ROS-Mediated Dual Role in Ferroptosis and Apoptosis via the MAPK Pathway in Human Osteosarcoma Cell Lines and Xenografts.2022Oxidative medicine and cellular longevity
  20. YAP knockdown in combination with ferroptosis induction increases the sensitivity of HOS human osteosarcoma cells to pyropheophorbide-α methyl ester-mediated photodynamic therapy.2022Photodiagnosis and photodynamic therapy
  21. Targeting X box-binding protein-1 (XBP1) enhances the sensitivity of HOS osteosarcoma cells to pyropheophorbide- α methyl ester-mediated photodynamic therapy.2022Photodiagnosis and photodynamic therapy
  22. Targeting GRP78 enhances the sensitivity of HOS osteosarcoma cells to pyropheophorbide-α methyl ester-mediated photodynamic therapy via the Wnt/β-catenin signaling pathway.2021Acta biochimica et biophysica Sinica
  23. Tetrandrine suppresses the growth of human osteosarcoma cells by regulating multiple signaling pathways.2021Bioengineered
  24. The role of vascular endothelial growth factor as a prognostic and clinicopathological marker in osteosarcoma: a systematic review and meta-analysis.2021Journal of orthopaedic surgery and research
  25. Bavachin Induces Ferroptosis through the STAT3/P53/SLC7A11 Axis in Osteosarcoma Cells.2021Oxidative medicine and cellular longevity
早期论文(2016–2020 年)15
  1. MiR-141-3p overexpression suppresses the malignancy of osteosarcoma by targeting FUS to degrade LDHB.2020Bioscience reports
  2. Antitumor effects and mechanisms of pyropheophorbide‑α methyl ester‑mediated photodynamic therapy on the human osteosarcoma cell line MG‑63.2020International journal of molecular medicine
  3. The role of miR-21/RECK in the inhibition of osteosarcoma by curcumin.2020Molecular and cellular probes
  4. MicroRNA-29b sensitizes osteosarcoma cells to doxorubicin by targeting matrix metalloproteinase 9 (MMP-9) in osteosarcoma.2019European review for medical and pharmacological sciences
  5. Honokiol suppresses proliferation and induces apoptosis via regulation of the miR‑21/PTEN/PI3K/AKT signaling pathway in human osteosarcoma cells.2018International journal of molecular medicine
  6. Synergistic inhibitory effects of capsaicin combined with cisplatin on human osteosarcoma in culture and in xenografts.2018Journal of experimental & clinical cancer research : CR
  7. TSSC3 promotes autophagy via inactivating the Src-mediated PI3K/Akt/mTOR pathway to suppress tumorigenesis and metastasis in osteosarcoma, and predicts a favorable prognosis.2018Journal of experimental & clinical cancer research : CR
  8. Effect and mechanisms of celastrol on the apoptosis of HOS osteosarcoma cells.2018Oncology reports
  9. Establishment and characterization of human osteosarcoma cells resistant to pyropheophorbide-α methyl ester-mediated photodynamic therapy.2017International journal of oncology
  10. Capsaicin inhibits proliferation and induces apoptosis in osteosarcoma cell lines via the mitogen‑activated protein kinase pathway.2017Oncology reports
  11. Apoptosis and autophagy induced by pyropheophorbide-α methyl ester-mediated photodynamic therapy in human osteosarcoma MG-63 cells.2016Apoptosis : an international journal on programmed cell death
  12. Down-regulation of S100A9 inhibits osteosarcoma cell growth through inactivating MAPK and NF-κB signaling pathways.2016BMC cancer
  13. Mitochondrial pathway and endoplasmic reticulum stress participate in the photosensitizing effectiveness of AE-PDT in MG63 cells.2016Cancer medicine
  14. Downregulation of RSK2 influences the biological activities of human osteosarcoma cells through inactivating AKT/mTOR signaling pathways.2016International journal of oncology
  15. Aloe-emodin-mediated photodynamic therapy induces autophagy and apoptosis in human osteosarcoma cell line MG‑63 through the ROS/JNK signaling pathway.2016Oncology reports

打开 PubMed 检索ClinicalTrials.gov

癌症

胃肠道间质瘤

Gastrointestinal stromal tumour

2021–2025 年中国大陆作者发表的 523 篇胃肠道间质瘤 PubMed 英文论文中,这家医院牵头了 12 篇,占 2.3%。

牵头论文
12
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 1120222023: 1120232024: 3320242025: 442025

重庆有 11 家医院列在胃肠道间质瘤下全国有 261 家医院列在胃肠道间质瘤下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Evaluate the Efficacy and Safety of Radiotherapy Combined With Ripretinib in the Treatment of Unresectable Advanced GIST
    分期
    不分期
    开始
    2024-05
    登记号
    NCT06507683

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:重庆医科大学附属第一医院重庆

  2. 正在招募
    Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
    分期
    II/III期
    开始
    2026-05
    登记号
    NCT07379047

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 31 家列出的医院为研究中心上海、北京、南京、南宁、南昌、合肥、哈尔滨、太原、广州、成都、昆明、杭州、武汉、济南、石家庄、福州、贵阳、郑州、重庆、长春、长沙、青岛

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室影像/核医学科肿瘤内科消化/肝病科
牵头的论文12
  1. Diagnostic Value of Contrast-Enhanced Ultrasound in Detecting Abdominal Metastases From Gastrointestinal Stromal Tumors.2026Journal of clinical ultrasound : JCU
  2. Development and validation of an ultrasound-based AI-radiomics model for diagnosing and risk-stratifying gastrointestional stromal tumors: a retrospective diagnostic study.2025BMC medical imaging
  3. Long-term outcomes of ripretinib versus sunitinib in Chinese patients with advanced gastrointestinal stromal tumor: An updated analysis of a phase 2 randomized clinical trial.2025CancerRCT
  4. The role of ultrasound in assessment and prediction of the efficacy of preoperative targeted therapy for gastrointestinal mesenchymal tumors compared with pathology.2025Journal of medical ultrasonics (2001)
  5. Investigation of Nutritional Status by GLIM Criteria in Outpatients with GIST.2025Nutrition and cancer
  6. Advanced gastrointestinal stromal tumor: reliable classification of imatinib plasma trough concentration via machine learning.2024BMC cancer
  7. Preoperative CT-based radiomics and deep learning model for predicting risk stratification of gastric gastrointestinal stromal tumors.2024Medical physics
  8. A case-matched study of imatinib mesylate between different formulations on plasma trough concentration, adverse events, quality of life and outcomes in gastrointestinal stromal tumor patients.2024PloS one
  9. Artificial intelligence-assisted endoscopic ultrasound in the diagnosis of gastrointestinal stromal tumors: a meta-analysis.2023Surgical endoscopy
  10. Escalation of radiotherapy dose in large locally advanced drug-resistant gastrointestinal stromal tumors by multi-shell simultaneous integrated boost intensity-modulated technique: a feasibility study.2022Radiation oncology (London, England)
  11. Ripretinib in treatment of repeatedly relapsing rectal gastrointestinal stromal tumor: a case report.2021Annals of palliative medicine
  12. Novel endoscopic management for small gastric submucosal tumors: A single-center experience (with video).2021Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
早期论文(2016–2020 年)4
  1. Therapeutic drug monitoring-based dose optimization for imatinib-associated serious cutaneous reactions in a patient with gastrointestinal stromal tumours: A case report.2020Journal of clinical pharmacy and therapeutics
  2. [Whole-course information management in gastrointestinal stromal tumor patients].2020Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  3. Relative Factors Analysis of Imatinib Trough Concentration in Chinese Patients with Gastrointestinal Stromal Tumor.2018Chemotherapy
  4. ShRNA-mediated BMI-1 gene silencing inhibits gastrointestinal stromal tumor cell telomerase activity and enhances apoptosis.2018The Kaohsiung journal of medical sciences
它在 ClinicalTrials.gov 上的全部试验(任何状态)5
  1. Evaluate the Efficacy and Safety of Radiotherapy Combined With Ripretinib in the Treatment of Unresectable Advanced GIST正在招募NCT06507683牵头方不分期2024-05 启动
  2. Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)正在招募NCT07379047研究中心II/III期2026-05 启动
  3. A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib已完成NCT04633122研究中心II期2020-11 启动
  4. A Study of CS3007 in Subjects With Gastrointestinal Stromal Tumor已完成NCT04254939研究中心I/II期2019-08 启动
  5. (VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST已完成NCT03465722研究中心III期2018-03 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

神经母细胞瘤

Neuroblastoma

2021–2025 年中国大陆作者发表的 1,132 篇神经母细胞瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.09%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

重庆有 10 家医院列在神经母细胞瘤下全国有 352 家医院列在神经母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的神经母细胞瘤开放试验。

这些数字背后的记录
论文中的科室神经内科

打开 PubMed 检索ClinicalTrials.gov

癌症

尤文肉瘤

Ewing sarcoma

2021–2025 年中国大陆作者发表的 163 篇尤文肉瘤 PubMed 英文论文中,这家医院牵头了 2 篇,占 1.2%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 2220222023: 0020232024: 0020242025: 002025

重庆有 5 家医院列在尤文肉瘤下全国有 139 家医院列在尤文肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的尤文肉瘤开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

血液疾病

多发性骨髓瘤

Multiple myeloma

2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 4 篇,占 0.2%。

牵头论文
4
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 0020222023: 0020232024: 0020242025: 222025

重庆有 4 家医院列在多发性骨髓瘤下全国有 178 家医院列在多发性骨髓瘤下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
    分期
    I期
    开始
    2026-05
    登记号
    NCT07477587

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 46 家列出的医院为研究中心上海、北京、南京、南昌、厦门、合肥、哈尔滨、天津、太原、宁波、广州、徐州、成都、无锡、杭州、武汉、沈阳、济南、深圳、温州、潍坊、石家庄、福州、苏州、蚌埠、贵阳、郑州、重庆、长沙、青岛

  2. 即将招募
    Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
    分期
    III期
    开始
    2026-06
    登记号
    NCT07569757

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 38 家列出的医院为研究中心上海、兰州、北京、南京、南宁、南昌、合肥、哈尔滨、太原、广州、徐州、成都、承德、昆明、杭州、株洲、沈阳、泸州、济南、湛江、石家庄、蚌埠、西安、贵阳、郑州、重庆、长沙、青岛

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题肾脏与骨骼并发症
论文中的科室肾内科

打开 PubMed 检索ClinicalTrials.gov

血液疾病

再生障碍性贫血

Aplastic anaemia

2021–2025 年中国大陆作者发表的 412 篇再生障碍性贫血 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.2%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

重庆有 4 家医院列在再生障碍性贫血下全国有 63 家医院列在再生障碍性贫血下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的再生障碍性贫血开放试验。

这些数字背后的记录
论文中的科室病理/检验科

打开 PubMed 检索ClinicalTrials.gov

血液疾病

β 地中海贫血

Beta thalassaemia

2021–2025 年中国大陆作者发表的 312 篇β 地中海贫血 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.3%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

重庆有 4 家医院列在β 地中海贫血下全国有 157 家医院列在β 地中海贫血下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的β 地中海贫血开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

视神经脊髓炎谱系疾病

Neuromyelitis optica spectrum disorder

2021–2025 年中国大陆作者发表的 485 篇视神经脊髓炎谱系疾病 PubMed 英文论文中,这家医院牵头了 8 篇,占 1.7%。

牵头论文
8
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 2220222023: 2220232024: 1120242025: 112025

重庆有 1 家医院列在视神经脊髓炎谱系疾病下全国有 67 家医院列在视神经脊髓炎谱系疾病下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 即将招募
    Crisugabalin in NMOSD Neuropathic Pain: A Randomized, Double-Blind, Placebo-Controlled Exploratory Trial
    分期
    IV期
    开始
    2026-06
    登记号
    NCT07699770

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:空军军医大学唐都医院;另有 5 家列出的医院为研究中心北京、昆明、沈阳、西安、重庆、长春

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题影像抗体与诊断生物制剂
论文中的科室影像/核医学科神经内科
牵头的论文8
  1. Radiomics-based analysis of choroid plexus abnormalities in neuromyelitis optica spectrum disorders and multiple sclerosis and their clinical implications.2025Multiple sclerosis and related disorders
  2. Comparison of diffusion tensor imaging (DTI) tissue characterization parameters in white matter tracts of patients with multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD).2024European radiology
  3. Enlarged choroid plexus related to cortical atrophy in multiple sclerosis.2023European radiology
  4. The case report of AQP4 and MOG IgG double positive NMOSD treated with subcutaneous Ofatumumab.2023Journal of neuroimmunology
  5. The different damage patterns of short-, middle- and long-range connections between patients with relapse-remitting multiple sclerosis and neuromyelitis optica spectrum disorder.2022Frontiers in immunology免费全文
  6. Expression and Clinical Correlation Analysis Between Repulsive Guidance Molecule a and Neuromyelitis Optica Spectrum Disorders.2022Frontiers in immunology免费全文
  7. Progressive brain microstructural damage in patients with multiple sclerosis but not in patients with neuromyelitis optica spectrum disorder: A cross-sectional and follow-up tract-based spatial statistics study.2021Multiple sclerosis and related disorders
  8. Altered structural networks in neuromyelitis optica spectrum disorder related with cognition impairment and clinical features.2021Multiple sclerosis and related disorders
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. Crisugabalin in NMOSD Neuropathic Pain: A Randomized, Double-Blind, Placebo-Controlled Exploratory Trial即将招募NCT07699770研究中心IV期2026-06 启动
  2. A Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum Disorders进行中,不再招募NCT06044350研究中心II期2023-08 启动
PubMed 以外找到的论文(未计入)5
  1. CM-MNet: A Coordinate Space-Aware Mamba-Based Multi-task Model for 3D Fine Lesions in Elongated Structures Segmentation and Diagnosis in MS and NMOSD2025Lecture notes in computer science会议论文
  2. Frequency-domain Decoupled Guided Feature Space Augmentation for Multi-Task Network in Few-Shot Diagnosis of Demyelinating Diseases2025Conference proceedings/Conference proceedings - IEEE International Conference on Systems, Man, and Cybernetics会议论文
  3. Point-of-care testing of neuromyelitis optica spectrum disorder using a sonochemically enhanced bifunctional CdTe-ZIF-8 nanohybrids-labelled lateral flow immunoassay2025Chemical Engineering Journal论文
  4. Ultrasensitive detection of aquaporin-4 antibodies using ZIF-67@PDA@PtCu nanocomposite-based electrochemical immunosensor for neuromyelitis optica spectrum disorder diagnosis2025Journal of Electroanalytical Chemistry论文
  5. Research progress of gut microbiome in autoimmune diseases of nervous system2022DOAJ (DOAJ: Directory of Open Access Journals)论文

打开 PubMed 检索ClinicalTrials.gov

其他疾病

IgG4相关性疾病

IgG4-related disease

2021–2025 年中国大陆作者发表的 246 篇IgG4相关性疾病 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.8%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 1120222023: 0020232024: 0020242025: 002025

重庆有 1 家医院列在IgG4相关性疾病下全国有 46 家医院列在IgG4相关性疾病下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的IgG4相关性疾病开放试验。

这些数字背后的记录
研究主题诊断与鉴别
牵头的论文2
  1. Think twice about IgG4-related diseases before operating on hepatic masses.2022Liver international : official journal of the International Association for the Study of the Liver
  2. IgG4-related disease manifesting as scrotal swelling.2021Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG

打开 PubMed 检索ClinicalTrials.gov

其他疾病

重症肌无力

Myasthenia gravis

2021–2025 年中国大陆作者发表的 499 篇重症肌无力 PubMed 英文论文中,这家医院牵头了 10 篇,占 2.0%。

牵头论文
10
2021–2025 年
牵头试验
2
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 2220222023: 0020232024: 3320242025: 442025

重庆有 1 家医院列在重症肌无力下全国有 93 家医院列在重症肌无力下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Myasthenia Gravis Registry in China
    分期
    未注明
    开始
    2024-02
    登记号
    NCT06241521

    年龄未注明(登记的条件)

    牵头:复旦大学附属华山医院;另有 15 家列出的医院为研究中心上海、北京、南昌、天津、广州、徐州、成都、苏州、西安、郑州、重庆、长春、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题危象与重症监护生物制剂与补体抑制剂抗体与诊断
论文中的科室神经内科
牵头的论文10
  1. Predictors of Quality of Life in Myasthenia Gravis Patients from Southwestern China: Validation of Clinical and Socioenvironmental Determinants.2026Neuroepidemiology
  2. Single-Cell Immune Profiling Reveals Neutrophils Promote Myasthenia Gravis Exacerbation Through BAFF Secretion.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  3. Postmarketing adverse events of efgartigimod alfa: a real-world pharmacovigilance study based on the FAERS database.2025BMJ open免费全文
  4. Hypothalamic kisspeptin alleviates myasthenia gravis by regulating Th1/Th17/Treg balance through Inhibition of NF-κB signaling pathway.2025Journal of neuroinflammation免费全文
  5. A systematic review of efgartigimod as an effective treatment for myasthenic crisis.2025Naunyn-Schmiedeberg's archives of pharmacology
  6. The Efficacy and Safety of Different Targeted Drugs for the Treatment of Generalized Myasthenia Gravis: A Systematic Review and Bayesian Network Meta-analysis.2024CNS drugs
  7. Case report: Rapid clinical improvement in acute exacerbation of MuSK-MG with efgartigimod.2024Frontiers in immunology免费全文
  8. Safety and neutralization antibody levels of inactivated SARS-CoV-2 vaccine in adult patients with Myasthenia Gravis: a prospective observational cohort study.2024Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  9. Single-cell mapping reveals dysregulation of immune cell populations and VISTA+ monocytes in myasthenia gravis.2022Clinical immunology (Orlando, Fla.)
  10. Refractory post-thymectomy myasthenia gravis with onset at MGFA stage V: a case report.2022Journal of cardiothoracic surgery免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)7
  1. Characteristics and Prognostic Outcomes of Diaphragmatic Ultrasound in Myasthenia Gravis已完成NCT06707727牵头方2024-07 启动
  2. A Prospective Cohort Study Of Myasthenia Gravis状态不明NCT04674605牵头方2020-12 启动
  3. Myasthenia Gravis Registry in China正在招募NCT06241521研究中心2024-02 启动
  4. A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)进行中,不再招募NCT06456580研究中心III期2024-07 启动
  5. A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis进行中,不再招募NCT06298552研究中心III期2024-04 启动
  6. A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis进行中,不再招募NCT06558279研究中心III期2024-09 启动
  7. A Study of TACI(Transmembrane Activator and Calcium-modulator and Cyclophilin Ligand (CAML) Interactor)-Antibody Fusion Protein Injection (RC18) in Subjects With Systemic Myasthenia Gravis已完成NCT04302103研究中心II期2020-07 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

抗 NMDA 受体脑炎

Anti-NMDA receptor encephalitis

2021–2025 年中国大陆作者发表的 264 篇抗 NMDA 受体脑炎 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.4%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

重庆有 2 家医院列在抗 NMDA 受体脑炎下全国有 126 家医院列在抗 NMDA 受体脑炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的抗 NMDA 受体脑炎开放试验。

这些数字背后的记录
论文中的科室影像/核医学科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

特发性肺纤维化

Idiopathic pulmonary fibrosis

2021–2025 年中国大陆作者发表的 989 篇特发性肺纤维化 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.3%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 1120232024: 0020242025: 112025

重庆有 6 家医院列在特发性肺纤维化下全国有 333 家医院列在特发性肺纤维化下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的特发性肺纤维化开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

肌萎缩侧索硬化症

Amyotrophic lateral sclerosis

2021–2025 年中国大陆作者发表的 779 篇肌萎缩侧索硬化症 PubMed 英文论文中,这家医院牵头了 5 篇,占 0.6%。

牵头论文
5
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 2220242025: 222025

重庆有 6 家医院列在肌萎缩侧索硬化症下全国有 194 家医院列在肌萎缩侧索硬化症下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肌萎缩侧索硬化症开放试验。

这些数字背后的记录
论文中的科室神经内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

杜氏肌营养不良

Duchenne muscular dystrophy

2021–2025 年中国大陆作者发表的 213 篇杜氏肌营养不良 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.5%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

重庆有 5 家医院列在杜氏肌营养不良下全国有 116 家医院列在杜氏肌营养不良下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的杜氏肌营养不良开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

白塞病

Behçet disease

2021–2025 年中国大陆作者发表的 245 篇白塞病 PubMed 英文论文中,这家医院牵头了 28 篇,占 11.4%。

牵头论文
28
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 8820212022: 6620222023: 7720232024: 5520242025: 222025

重庆有 7 家医院列在白塞病下全国有 149 家医院列在白塞病下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    AutoInflammatory Disease Alliance Registry (AIDA)
    分期
    未注明
    开始
    2020-08
    登记号
    NCT05200715

    年龄未注明(登记的条件)

    牵头方不是列出的医院;另有 2 家列出的医院为研究中心北京、重庆

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室眼科/神经眼科
牵头的论文28
  1. Proteomic Profiles of Neutrophils from Behcet's Uveitis Patients and their Sex Differences.2025Inflammation
  2. DNA 5-Hydroxymethylcytosine Landscape and Transcriptional Profile Highlight the TUBB4B-Mediated Th17/Th1/Treg Imbalance in Behçet's Uveitis.2025Investigative ophthalmology & visual science
  3. Plasma-derived exosomal protein SHP2 deficiency induces neutrophil hyperactivation in Behcet's uveitis.2024Experimental eye research
  4. 4-Octyl Itaconate Inhibits Proinflammatory Cytokine Production in Behcet's Uveitis and Experimental Autoimmune Uveitis.2024Inflammation
  5. Association of Long Non-coding RNA C1RL-AS1 and PTPN6 Gene Polymorphisms with Ocular Behcet's Disease in Han Chinese.2024Ocular immunology and inflammation
  6. Sensitive optical coherence tomography angiography parameters detecting retinal vascular changes in Behcet's uveitis.2024Photodiagnosis and photodynamic therapy
  7. Combinations of immunomodulatory agents for prevention of uveitis relapse in patients with severe Behçet's disease already on corticosteroid therapy: a randomised, open-label, head-to-head trial.2024The Lancet. RheumatologyRCT
  8. Association of Behçet's disease with the risk of metabolic syndrome and its components: a systematic review and meta-analysis.2023Clinical and experimental medicine
  9. Interferon-α2a induces CD4+ T cell apoptosis and suppresses Th1/Th17 responses via upregulating IRF1-mediated PDL1 expression in dendritic cells from Behcet's uveitis.2023Clinical immunology (Orlando, Fla.)
  10. IL-8 Triggers Neutrophil Extracellular Trap Formation Through an Nicotinamide Adenine Dinucleotide Phosphate Oxidase- and Mitogen-Activated Protein Kinase Pathway-Dependent Mechanism in Uveitis.2023Investigative ophthalmology & visual science
  11. Effects of Plasma-Derived Exosomal miRNA-19b-3p on Treg/T Helper 17 Cell Imbalance in Behçet's Uveitis.2023Investigative ophthalmology & visual science
  12. Gut microbial signatures and their functions in Behcet's uveitis and Vogt-Koyanagi-Harada disease.2023Journal of autoimmunity
  13. Risk factors, clinical features and treatment of Behçet's disease uveitis.2023Progress in retinal and eye research
  14. ANALYSIS OF VASCULAR CHANGES OF FUNDUS IN BEHCET UVEITIS BY WIDEFIELD SWEPT SOURCE OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY AND FUNDUS FLUORESCEIN ANGIOGRAPHY.2023Retina (Philadelphia, Pa.)
  15. Identification of Novel Risk Loci for Behçet's Disease-Related Uveitis in a Chinese Population in a Genome-Wide Association Study.2022Arthritis & rheumatology (Hoboken, N.J.)
  16. The pro-inflammatory effect of triglyceride on human CD4+ T cells and experimental autoimmune uveitis.2022Clinical immunology (Orlando, Fla.)
  17. Transcriptomic profiling of iris tissue highlights LCK signaling and T cell-mediated immunity in Behcet's uveitis.2022Journal of autoimmunity
  18. Progranulin Suppressed Autoimmune Uveitis and Autoimmune Neuroinflammation by Inhibiting Th1/Th17 Cells and Promoting Treg Cells and M2 Macrophages.2022Neurology(R) neuroimmunology & neuroinflammation
  19. SNP rs7130280 in lncRNA NONHSAT159216.1 confers susceptibility to Behçet's disease uveitis in a Chinese Han population.2022Rheumatology (Oxford, England)
  20. Evaluation of sensitivity and specificity of diagnostic criteria for Behçet's disease in the absence of a gold standard.2022Rheumatology (Oxford, England)
  21. Decreased microRNA-155 in Behcet's disease leads to defective control of autophagy thereby stimulating excessive proinflammatory cytokine production.2021Arthritis research & therapy
  22. Higher 25-hydroxyvitamin D level is associated with increased risk for Behçet's disease.2021Clinical nutrition (Edinburgh, Scotland)
  23. SNP-mediated binding of TBX1 to the enhancer element of IL-10 reduces the risk of Behçet's disease.2021Epigenomics
  24. Metabolomic Analysis of Aqueous Humor Identifies Aberrant Amino Acid and Fatty Acid Metabolism in Vogt-Koyanagi-Harada and Behcet's Disease.2021Frontiers in immunology
  25. Specific sweat metabolite profile in ocular Behcet's disease.2021International immunopharmacology
  26. Tuberculosis Exposure With Risk of Behçet Disease Among Patients With Uveitis.2021JAMA ophthalmology
  27. The Rs12569232 SNP Association with Vogt-Koyanagi-Harada Disease and Behcet's Disease is Probably Mediated by Regulation of Linc00467 Expression.2021Ocular immunology and inflammation
  28. Prevalence and clinical features of systemic diseases in Chinese patients with uveitis.2021The British journal of ophthalmology
中文论文(未计入)1
  1. [Literature data mining on the current research status of uveitis in China].2024[Zhonghua yan ke za zhi] Chinese journal of ophthalmology
早期论文(2016–2020 年)29
  1. Weak association of a TNFRSF1A polymorphism with Behcet's disease in Chinese Han.2020Experimental eye research
  2. Uveitis genetics.2020Experimental eye research
  3. Aqueous cytokine levels in four common uveitis entities.2020International immunopharmacology
  4. Different Methylation of CpG-SNPs in Behcet's Disease.2019BioMed research international
  5. UVEOGENE: An SNP database for investigations on genetic factors associated with uveitis and their relationship with other systemic autoimmune diseases.2019Human mutation
  6. Long-Term Efficacy and Safety of Interferon Alpha-2a in the Treatment of Chinese Patients with Behçet's Uveitis Not Responding to Conventional Therapy.2019Ocular immunology and inflammation
  7. Epigenome-wide association study identifies Behçet's disease-associated methylation loci in Han Chinese.2019Rheumatology (Oxford, England)
  8. Association of Long Noncoding RNAs Polymorphisms With Ankylosing Spondylitis, Vogt-Koyanagi-Harada Disease, and Behcet's Disease.2018Investigative ophthalmology & visual science
  9. A metagenomic study of the gut microbiome in Behcet's disease.2018Microbiome
  10. Analysis of the association between Fc receptor family gene polymorphisms and ocular Behçet's disease in Han Chinese.2018Scientific reports
  11. Association of LACC1, CEBPB-PTPN1, RIPK2 and ADO-EGR2 with ocular Behcet's disease in a Chinese Han population.2018The British journal of ophthalmology
  12. Decreased expression of A20 is associated with ocular Behcet's disease (BD) but not with Vogt-Koyanagi-Harada (VKH) disease.2018The British journal of ophthalmology
  13. Association of genetic variations in PTPN2 and CD122 with ocular Behcet's disease.2018The British journal of ophthalmology
  14. The Association of Chemokine Gene Polymorphisms with VKH and Behcet's Disease in a Chinese Han Population.2017BioMed research international
  15. Increased Complement 3a Receptor is Associated with Behcet's disease and Vogt-Koyanagi-Harada disease.2017Scientific reports
  16. Genetic polymorphisms of C-type lectin receptors in Behcet's disease in a Chinese Han population.2017Scientific reports
  17. Identification of susceptibility SNPs in IL10 and IL23R-IL12RB2 for Behçet's disease in Han Chinese.2017The Journal of allergy and clinical immunology
  18. Higher Expression of NOD1 and NOD2 is Associated with Vogt-Koyanagi-Harada (VKH) Syndrome But Not Behcet's Disease (BD).2016Current molecular medicine
  19. Association of a NOS3 gene polymorphism with Behçet's disease but not with Vogt-Koyanagi-Harada syndrome in Han Chinese.2016Molecular vision
  20. Genetic Variation in the REL Gene Increases Risk of Behcet's Disease in a Chinese Han Population but That of PRKCQ Does Not.2016PloS one
  21. Association of TNFSF4 Polymorphisms with Vogt-Koyanagi-Harada and Behcet's Disease in Han Chinese.2016Scientific reports
  22. Genetic analysis of innate immunity in Behcet's disease identifies an association with IL-37 and IL-18RAP.2016Scientific reports
  23. Analysis of receptor tyrosine kinase genetics identifies two novel risk loci in GAS6 and PROS1 in Behçet's disease.2016Scientific reports
  24. Genetic polymorphisms of cell adhesion molecules in Behcet's disease in a Chinese Han population.2016Scientific reports
  25. Association between Functional MICA-TM and Behcet's Disease: A Systematic Review and Meta-analysis.2016Scientific reports
  26. Decreased B and T lymphocyte attenuator in Behcet's disease may trigger abnormal Th17 and Th1 immune responses.2016Scientific reports
  27. Genetic Variations of NLR family genes in Behcet's Disease.2016Scientific reports
  28. miR-23a, miR-146a and miR-301a confer predisposition to Vogt-Koyanagi-Harada syndrome but not to Behcet's disease.2016Scientific reports
  29. Two Genetic Variations in the IRF8 region are associated with Behçet's disease in Han Chinese.2016Scientific reports
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. AutoInflammatory Disease Alliance Registry (AIDA)正在招募NCT05200715研究中心2020-08 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

IgA 肾病

IgA nephropathy

2021–2025 年中国大陆作者发表的 736 篇IgA 肾病 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.1%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

重庆有 14 家医院列在IgA 肾病下全国有 346 家医院列在IgA 肾病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的IgA 肾病开放试验。

这些数字背后的记录
论文中的科室影像/核医学科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

遗传性大疱性表皮松解症

Inherited epidermolysis bullosa

2021–2025 年中国大陆作者发表的 56 篇遗传性大疱性表皮松解症 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.8%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

重庆有 4 家医院列在遗传性大疱性表皮松解症下全国有 41 家医院列在遗传性大疱性表皮松解症下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的遗传性大疱性表皮松解症开放试验。

这些数字背后的记录
牵头的论文1
  1. Successful use of tofacitinib in epidermolysis bullosa pruriginosa.2022Clinical and experimental dermatology

打开 PubMed 检索ClinicalTrials.gov

其他相关研究

联系这家医院

出示给工作人员或司机的院名卡

重庆医科大学附属第一医院

First Affiliated Hospital of Chongqing Medical University

重庆

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请在医院官网查询相关科室。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR Wikidata
he First Affiliated Hospital of Chongqing Medical University; First affiliated Hospital of Chongqing Medical University; First Affiliated Hospital of Chongqing Medical Universit; First Branch of The First Affiliated Hospital; Affiliated Yongchuan Hospital of Chongqing Medical University; The Affiliated Yongchuan Hospital of Chongqing Medical University; 重庆医科大学附属永川医院

提出更正下载数据